Showing results (271-280 of 480) with videos related to
Sort By:
Pageof 48
Liver International : Official Journal of the International Association for the Study of the Liver|March 26, 2014
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)Paul H Hayashi, Huiman X Barnhart, Robert J Fontana, et al.Epidemiology (Cambridge, Mass.)|January 31, 2023
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.Journal of Hepatology|September 10, 2002
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.The American Journal of Gastroenterology|June 18, 2003
Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practiceMitchell L Shiffman, Andrea Ferreira-Gonzalez, K Rajender Reddy, et al.The American Journal of Gastroenterology|July 6, 2004
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.Gastroenterology|April 1, 2014
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onsetRobert J Fontana, Paul H Hayashi, Jiezhun Gu, et al.The American Journal of Gastroenterology|November 27, 2024
Sex Differences in Patient-Reported Outcomes and Perception of Ascites Burden Among Outpatients With Decompensated Cirrhosis and AscitesFlorence Wong, K Rajender Reddy, Puneeta Tandon, et al.Cancer|January 26, 2011
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinomaWeijing Sun, Davendra Sohal, Daniel G Haller, et al.Pageof 48